DESMOTABS

4mg. The need for continued treatment should be reassessed after 3 months by means of a period of at least 1 week without Desmotabs

Side-effects include headache, stomach pain and nausea. Isolated cases of allergic skin reactions and more severe general allergic reactions have been reported. Very rare cases of emotional disorders including aggression in children have been reported.

Treatment with desmopressin without concomitant reduction of fluid intake may lead to water retention/hyponatraemia with accompanying symptoms of headache, nausea, vomiting, weight gain, decreased serum sodium and in serious cases, convulsions.

Care should be taken with patients who have reduced renal function and/or cardiovascular disease or cystic fibrosis. In chronic renal disease the antidiuretic effect of Desmotabs would be less than normal. When Desmotabs are used for the treatment of enuresis, fluid intake must be limited from 1 hour before taking the tablets at bedtime until the next morning and in any case for a minimum of 8 hours after administration.

Patients being treated for primary nocturnal enuresis should be warned to avoid ingesting water while swimming and to discontinue Desmotabs during an episode of vomiting and/or diarrhoea until their fluid balance is once again normal.

Special precautions:

Precautions to prevent fluid overload must be taken in: - conditions characterised by fluid and/or electrolyte imbalance - patients at risk for increased intracranial pressure

Desmotabs are contraindicated in cases of cardiac insufficiency and other conditions requiring treatment with diuretic agents. Desmotabs should only be used in patients with normal blood pressure. Before prescribing Desmotabs the diagnoses of psychogenic polydipsia and alcohol abuse should be excluded.

Desmopressin should not be prescribed to patients over the age of 65 for the treatment of primary nocturnal enuresis.